B-Cell IgE RNA Profiling for Predicting Allergic Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current allergy tests lack the ability to predict future allergic responses and are limited by the need for specific capture antibodies, potential cross-reactivity, and the risk of severe reactions during contact-based testing, which can lag behind allergen discovery.
Innovation Solution
Measuring RNA from B cells that encode the Immunoglobulin E (IgE) constant region, particularly nonproductive epsilon germline transcripts (εGLTs), to predict allergic responses by determining the propensity for antibody class switch recombination to IgE, allowing for accurate prediction of allergy predisposition and specific allergens causing reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If ELISA-based serum IgE testing is used, then allergy testing can be performed with antibody-based methods, but the tests are low-throughput and require unique capture antibodies for every allergen tested
Solution Approach 1:
The patent extracts the essential information needed for allergy testing by measuring only IgE antibody levels and specific IgE/allergen ratios, eliminating the need for complex capture antibody panels and multiple allergen-specific assays. This extraction approach maintains diagnostic capability while reducing system complexity.
Solution Approach 2:
The invention creates a universal testing method that can assess multiple allergens and predict future allergic responses using a single standardized assay platform. This multi-functional approach replaces the need for allergen-specific capture antibodies with a universal IgE measurement system that works across different allergen types.
2Measurement precision
If contact-based allergy testing (skin prick tests, patch tests, intradermal tests, or oral food challenges) is used, then high sensitivity can be achieved, but the specificity can be low and there is risk of severe allergic responses
Solution Approach 1:
The patent performs preliminary measurement of current IgE levels and establishes baseline data before potential allergen exposure. By measuring IgE antibodies in advance and comparing against allergen-specific thresholds, the system predicts future allergic responses without requiring actual allergen contact, thereby preventing severe reactions while maintaining diagnostic accuracy.
Solution Approach 2:
The invention uses IgE antibody levels as an intermediary marker that indirectly indicates allergic sensitivity without requiring direct allergen-subject contact. This mediator approach allows assessment of allergic risk through blood-based IgE measurement rather than direct exposure testing, eliminating the harmful effects of severe allergic responses while preserving diagnostic capability.
3Measurement precision
If contact-based allergy testing is used, then high sensitivity can be achieved, but rigorous safety testing is required which means allergy testing can lag allergen discovery
Solution Approach 1:
The patent employs a simplified, standardized IgE measurement assay that does not require expensive, time-consuming safety validation for each new allergen. By using a universal blood-based IgE test rather than complex contact testing protocols, the system can rapidly assess new allergens without rigorous safety testing delays, enabling faster allergen discovery and testing implementation.
4Ease of manufacture
If ELISA-based serum IgE testing is used, then antibody-based allergy testing can be performed, but cross-reactivity between allergens can obfuscate results
Solution Approach 1:
The patent applies local quality analysis by calculating specific IgE/allergen ratios that compare IgE levels against allergen-specific thresholds. This localized assessment approach distinguishes true allergic responses from cross-reactivity by evaluating each allergen individually against its own baseline, thereby clarifying results that would otherwise be obfuscated by cross-reactivity between different allergens.
Data Source
AI summary
The present invention provides systems and methods for predicting an allergic response in a subject by measuring the amounts of RNA species from B cells that encode at least a part of the Immunoglobulin E (IgE) constant region (Cε), such as nonproductive epsilon germline transcripts (εGLTs).